Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey S Freeman

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Mayo Clinic Proceedings|November 26, 2010
A physiologic and pharmacological basis for implementation of incretin hormones in the treatment of type 2 diabetes mellitusJeffrey S Freeman
The Journal of the American Osteopathic Association|July 21, 2010
Illustrative case and discussion: a 58-year-old man with diabetesJeffrey S Freeman
The Journal of the American Osteopathic Association|September 6, 2007
Reducing the "domino effect" of the metabolic syndromeJeffrey S Freeman
The Journal of the American Osteopathic Association|September 10, 2003
Diabetes-related clinical issues represented by the "Faces of Diabetes"Jeffrey S Freeman
The Journal of the American Osteopathic Association|March 11, 2011
Optimizing outcomes for GLP-1 agonistsJeffrey S Freeman
The Journal of the American Osteopathic Association|April 13, 2010
New therapeutic options: management strategies to optimize glycemic controlJeffrey S Freeman
The Journal of the American Osteopathic Association|January 24, 2012
Improving glucagon-like peptide-1 dynamics in patients with type 2 diabetes mellitusJeffrey S Freeman
Postgraduate Medicine|June 11, 2013
Review of insulin-dependent and insulin-independent agents for treating patients with type 2 diabetes mellitus and potential role for sodium-glucose co-transporter 2 inhibitorsJeffrey S Freeman
Drugs in Context|January 17, 2014
Initial combination therapy for patients with type 2 diabetes mellitus: considerations for metformin plus linagliptinJeffrey S Freeman
The Journal of the American Osteopathic Association|September 19, 2007
The pathophysiologic role of incretinsJeffrey S Freeman
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Mayo Clinic Proceedings|November 26, 2010
A physiologic and pharmacological basis for implementation of incretin hormones in the treatment of type 2 diabetes mellitusJeffrey S Freeman
The Journal of the American Osteopathic Association|July 21, 2010
Illustrative case and discussion: a 58-year-old man with diabetesJeffrey S Freeman
The Journal of the American Osteopathic Association|September 6, 2007
Reducing the "domino effect" of the metabolic syndromeJeffrey S Freeman
The Journal of the American Osteopathic Association|September 10, 2003
Diabetes-related clinical issues represented by the "Faces of Diabetes"Jeffrey S Freeman
The Journal of the American Osteopathic Association|March 11, 2011
Optimizing outcomes for GLP-1 agonistsJeffrey S Freeman
The Journal of the American Osteopathic Association|April 13, 2010
New therapeutic options: management strategies to optimize glycemic controlJeffrey S Freeman
The Journal of the American Osteopathic Association|January 24, 2012
Improving glucagon-like peptide-1 dynamics in patients with type 2 diabetes mellitusJeffrey S Freeman
Postgraduate Medicine|June 11, 2013
Review of insulin-dependent and insulin-independent agents for treating patients with type 2 diabetes mellitus and potential role for sodium-glucose co-transporter 2 inhibitorsJeffrey S Freeman
Drugs in Context|January 17, 2014
Initial combination therapy for patients with type 2 diabetes mellitus: considerations for metformin plus linagliptinJeffrey S Freeman
The Journal of the American Osteopathic Association|September 19, 2007
The pathophysiologic role of incretinsJeffrey S Freeman
Pageof 3